![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IGKC |
Gene summary for IGKC |
![]() |
Gene information | Species | Human | Gene symbol | IGKC | Gene ID | 3514 |
Gene name | immunoglobulin kappa constant | |
Gene Alias | HCAK1 | |
Cytomap | 2p11.2 | |
Gene Type | other | GO ID | GO:0001775 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3514 | IGKC | GSM4909281 | Human | Breast | IDC | 3.56e-16 | 3.07e-01 | 0.21 |
3514 | IGKC | GSM4909282 | Human | Breast | IDC | 2.96e-13 | 3.01e-01 | -0.0288 |
3514 | IGKC | GSM4909287 | Human | Breast | IDC | 2.36e-16 | 4.32e-01 | 0.2057 |
3514 | IGKC | GSM4909288 | Human | Breast | IDC | 4.62e-29 | 1.26e+00 | 0.0988 |
3514 | IGKC | GSM4909290 | Human | Breast | IDC | 1.79e-96 | 1.51e+00 | 0.2096 |
3514 | IGKC | GSM4909291 | Human | Breast | IDC | 2.17e-52 | 1.06e+00 | 0.1753 |
3514 | IGKC | GSM4909294 | Human | Breast | IDC | 5.86e-13 | 4.34e-01 | 0.2022 |
3514 | IGKC | GSM4909298 | Human | Breast | IDC | 3.71e-07 | 2.15e-01 | 0.1551 |
3514 | IGKC | GSM4909300 | Human | Breast | IDC | 1.98e-18 | 6.56e-01 | 0.0334 |
3514 | IGKC | GSM4909305 | Human | Breast | IDC | 6.69e-08 | 2.92e-01 | 0.0436 |
3514 | IGKC | GSM4909306 | Human | Breast | IDC | 4.57e-03 | 1.28e-01 | 0.1564 |
3514 | IGKC | GSM4909308 | Human | Breast | IDC | 1.93e-14 | 3.68e-01 | 0.158 |
3514 | IGKC | GSM4909309 | Human | Breast | IDC | 4.14e-21 | 6.05e-01 | 0.0483 |
3514 | IGKC | GSM4909316 | Human | Breast | IDC | 4.36e-02 | 3.99e-01 | 0.21 |
3514 | IGKC | GSM4909317 | Human | Breast | IDC | 8.19e-72 | 1.06e+00 | 0.1355 |
3514 | IGKC | GSM4909318 | Human | Breast | IDC | 2.65e-03 | 5.27e-01 | 0.2031 |
3514 | IGKC | M1 | Human | Breast | IDC | 5.99e-76 | 1.34e+00 | 0.1577 |
3514 | IGKC | NCCBC5 | Human | Breast | DCIS | 1.25e-12 | 6.25e-01 | 0.2046 |
3514 | IGKC | P3 | Human | Breast | IDC | 3.72e-06 | 4.98e-01 | 0.1542 |
3514 | IGKC | DCIS2 | Human | Breast | DCIS | 3.32e-17 | 8.50e-02 | 0.0085 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000276421 | Cervix | N_HPV | immune response-regulating signaling pathway | 36/534 | 468/18723 | 7.52e-08 | 7.81e-06 | 36 |
GO:004274211 | Cervix | N_HPV | defense response to bacterium | 28/534 | 350/18723 | 9.96e-07 | 5.53e-05 | 28 |
GO:005125121 | Cervix | N_HPV | positive regulation of lymphocyte activation | 28/534 | 362/18723 | 1.93e-06 | 9.68e-05 | 28 |
GO:001606411 | Cervix | N_HPV | immunoglobulin mediated immune response | 20/534 | 207/18723 | 2.10e-06 | 1.01e-04 | 20 |
GO:000189522 | Cervix | N_HPV | retina homeostasis | 12/534 | 79/18723 | 2.31e-06 | 1.07e-04 | 12 |
GO:001972411 | Cervix | N_HPV | B cell mediated immunity | 20/534 | 210/18723 | 2.63e-06 | 1.17e-04 | 20 |
GO:000189424 | Cervix | N_HPV | tissue homeostasis | 23/534 | 268/18723 | 2.86e-06 | 1.24e-04 | 23 |
GO:006024923 | Cervix | N_HPV | anatomical structure homeostasis | 24/534 | 314/18723 | 1.27e-05 | 4.17e-04 | 24 |
GO:001032421 | Cervix | N_HPV | membrane invagination | 15/534 | 144/18723 | 1.60e-05 | 4.86e-04 | 15 |
GO:00069111 | Cervix | N_HPV | phagocytosis, engulfment | 14/534 | 127/18723 | 1.61e-05 | 4.86e-04 | 14 |
GO:000225321 | Cervix | N_HPV | activation of immune response | 26/534 | 375/18723 | 3.06e-05 | 8.02e-04 | 26 |
GO:00990241 | Cervix | N_HPV | plasma membrane invagination | 14/534 | 136/18723 | 3.49e-05 | 8.79e-04 | 14 |
GO:000695611 | Cervix | N_HPV | complement activation | 13/534 | 130/18723 | 8.91e-05 | 1.86e-03 | 13 |
GO:00027682 | Cervix | N_HPV | immune response-regulating cell surface receptor signaling pathway | 22/534 | 315/18723 | 1.11e-04 | 2.18e-03 | 22 |
GO:005085111 | Cervix | N_HPV | antigen receptor-mediated signaling pathway | 17/534 | 240/18723 | 5.54e-04 | 7.40e-03 | 17 |
GO:00024551 | Cervix | N_HPV | humoral immune response mediated by circulating immunoglobulin | 11/534 | 121/18723 | 6.92e-04 | 8.86e-03 | 11 |
GO:00069581 | Cervix | N_HPV | complement activation, classical pathway | 10/534 | 108/18723 | 1.04e-03 | 1.21e-02 | 10 |
GO:00508641 | Cervix | N_HPV | regulation of B cell activation | 14/534 | 198/18723 | 1.69e-03 | 1.72e-02 | 14 |
GO:00024291 | Cervix | N_HPV | immune response-activating cell surface receptor signaling pathway | 18/534 | 291/18723 | 1.83e-03 | 1.82e-02 | 18 |
GO:00027571 | Cervix | N_HPV | immune response-activating signal transduction | 18/534 | 291/18723 | 1.83e-03 | 1.82e-02 | 18 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGKC | SNV | Missense_Mutation | novel | c.63A>C | p.Thr22Pro | p.T22P | IG_C_gene | tolerated(0.15) | possibly_damaging(0.73) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
IGKC | SNV | Missense_Mutation | novel | c.161N>C | p.Glu54Asp | p.E54D | IG_C_gene | tolerated(0.36) | benign(0) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.90N>G | p.Asn31Asp | p.N31D | IG_C_gene | tolerated(0.57) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.154N>A | p.Ser52Tyr | p.S52Y | IG_C_gene | deleterious(0) | benign(0.065) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | rs373698975 | c.145N>T | p.Ser49Leu | p.S49L | IG_C_gene | deleterious(0.05) | benign(0.418) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
IGKC | SNV | Missense_Mutation | novel | c.58N>A | p.Ser20Tyr | p.S20Y | IG_C_gene | deleterious(0) | probably_damaging(0.938) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
IGKC | SNV | Missense_Mutation | novel | c.141C>A | p.Gln48Lys | p.Q48K | IG_C_gene | tolerated(0.65) | benign(0.013) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.61N>A | p.Gly21Glu | p.G21E | IG_C_gene | deleterious(0.05) | possibly_damaging(0.777) | TCGA-NJ-A4YG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.217N>A | p.Thr73Lys | p.T73K | IG_C_gene | deleterious(0) | possibly_damaging(0.893) | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.274N>G | p.Gln92Arg | p.Q92R | IG_C_gene | tolerated(0.06) | benign(0.03) | TCGA-63-A5MI-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | vinorelbine | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |